TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-Center, RCT Evaluating the Safety and Effectiveness of Coolief™ Cooled Radiofrequency Probe to Create Lesions of the Genicular Nerves and Comparing Corticosteroid Injection in the Management of Knee Pain
Brief Summary: This study is designed to:

* Determine the effectiveness (primarily measured by pain relief) of Coolief when used to create radiofrequency lesions of the genicular nerves compared to pain relief following corticosteroid injection; and
* Confirm the safety of Coolief when used to perform radiofrequency lesions of the genicular nerves in subjects to manage knee pain compared to safety of corticosteroid injection


Options:
A: Arm Label: radiofrequency group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: radiofrequency | Arm Label: conventional group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol (conventional), Drug: Ketorolac Tromethamine (conventional) | Intervention Type: PROCEDURE; Name: radiofrequency; Assigned to Arm(s): radiofrequency group | Intervention Type: DRUG; Name: Paracetamol (conventional); Assigned to Arm(s): conventional group | Intervention Type: DRUG; Name: Ketorolac Tromethamine (conventional); Assigned to Arm(s): conventional group
B: Arm Label: All Enrolled Participants; Type: N/A; Interventions: Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Intervention Type: DRUG; Name: Standard of care for treatment of osteoarthritis (OA) of knee(s); Assigned to Arm(s): All Enrolled Participants
C: Arm Label: Cooled radiofrequency; Type: EXPERIMENTAL; Interventions: Device: Cooled Radiofrequency | Arm Label: Corticosteroid injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Corticosteroid injection | Intervention Type: DEVICE; Name: Cooled Radiofrequency; Assigned to Arm(s): Cooled radiofrequency | Intervention Type: DRUG; Name: Corticosteroid injection; Assigned to Arm(s): Corticosteroid injection
D: Arm Label: Conventional Radiofrequency of the genicular nerves; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Radiofrequency ablation of the genicular nerves | Arm Label: Cooled Radiofrequency of the genicular nerves; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cooled Radiofrequency ablation of the genicular nerves | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: PROCEDURE; Name: Conventional Radiofrequency ablation of the genicular nerves; Assigned to Arm(s): Conventional Radiofrequency of the genicular nerves | Intervention Type: PROCEDURE; Name: Cooled Radiofrequency ablation of the genicular nerves; Assigned to Arm(s): Cooled Radiofrequency of the genicular nerves | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Collaborative Self-Management Patient Education Will Improve Health Outcomes in COPD
Brief Summary: The overall objective of this study is to evaluate a collaborative self-management intervention in patients with moderate to severe COPD in a primary care population. To achieve this objective the investigators developed a diagnostic and treatment pathway for the management of COPD in primary care that is based on national guidelines and focused on patient self-management.

.


Options:
A: Arm Label: Case Management and Self-Management Education; Type: EXPERIMENTAL; Interventions: Other: Case Management and Self-Management Education | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Case Management and Self-Management Education | Intervention Type: OTHER; Name: Case Management and Self-Management Education; Assigned to Arm(s): Case Management and Self-Management Education, Usual Care
B: Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Case Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Case Management; Assigned to Arm(s): Case Management
C: Arm Label: Pulmonary daoyin therapy of China; Type: EXPERIMENTAL; Interventions: Other: Pulmonary daoyin therapy of China | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: OTHER; Name: Pulmonary daoyin therapy of China; Assigned to Arm(s): Pulmonary daoyin therapy of China | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Control
D: Arm Label: Feedback; Type: EXPERIMENTAL; Interventions: Device: Feedback | Arm Label: Demonstration; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Feedback; Assigned to Arm(s): Feedback | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Demonstration

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Collaborative Self-Management Patient Education Will Improve Health Outcomes in COPD
Brief Summary: The overall objective of this study is to evaluate a collaborative self-management intervention in patients with moderate to severe COPD in a primary care population. To achieve this objective the investigators developed a diagnostic and treatment pathway for the management of COPD in primary care that is based on national guidelines and focused on patient self-management.

.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Web Platform | Intervention Type: OTHER; Name: Web Platform; Assigned to Arm(s): Intervention group
B: Arm Label: Case Management and Self-Management Education; Type: EXPERIMENTAL; Interventions: Other: Case Management and Self-Management Education | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Case Management and Self-Management Education | Intervention Type: OTHER; Name: Case Management and Self-Management Education; Assigned to Arm(s): Case Management and Self-Management Education, Usual Care
C: Arm Label: Person-centred care at distance; Type: EXPERIMENTAL; Interventions: Behavioral: Person-centred care at distance | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Person-centred care at distance; Assigned to Arm(s): Person-centred care at distance
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: breathing retraining, Other: exercise training | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: exercise training | Intervention Type: OTHER; Name: breathing retraining; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: exercise training; Assigned to Arm(s): Arm 1, Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group
Brief Summary: This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma. The study also included a substudy to evaluate safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, Drug: irinotecan | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 2
B: Arm Label: Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Procedure: quality-of-life assessment | Arm Label: Radiation; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Procedure: quality-of-life assessment, Radiation: Radiation | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Radiation
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: VB-111 + bevacizumab | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: VB-111 + bevacizumab; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2
D: Arm Label: ABT-414/temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin, Drug: Temozolomide | Arm Label: ABT-414_adult; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin | Arm Label: Control_lomustine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine | Arm Label: Control_ temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Arm Label: ABT-414_ pediatric; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin | Intervention Type: DRUG; Name: Depatuxizumab mafodotin; Assigned to Arm(s): ABT-414/temozolomide, ABT-414_ pediatric, ABT-414_adult | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): ABT-414/temozolomide, Control_ temozolomide | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): Control_lomustine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group
Brief Summary: This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma. The study also included a substudy to evaluate safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population.


Options:
A: Arm Label: Cediranib & Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: gefitinib | Arm Label: Cediranbib & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: Placebo | Intervention Type: DRUG; Name: cediranib maleate; Assigned to Arm(s): Cediranbib & placebo, Cediranib & Gefitinib | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Cediranib & Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cediranbib & placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
C: Arm Label: ABT-414/temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin, Drug: Temozolomide | Arm Label: ABT-414_adult; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin | Arm Label: Control_lomustine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine | Arm Label: Control_ temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Arm Label: ABT-414_ pediatric; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin | Intervention Type: DRUG; Name: Depatuxizumab mafodotin; Assigned to Arm(s): ABT-414/temozolomide, ABT-414_ pediatric, ABT-414_adult | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): ABT-414/temozolomide, Control_ temozolomide | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): Control_lomustine
D: Arm Label: Cilengitide + Temozolomide + Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cilengitide, Drug: Temozolomide, Radiation: Radiotherapy | Arm Label: Temozolomide + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cilengitide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Application of Appropriate Technology for Obesity Prevention and Control in Seven Centers in China
Brief Summary: The study was designed as a national multi-centered cluster randomized controlled trial involving more than 70,000 children and adolescents aged 7-18 years from 7 provinces in China. In each center, about 12-16 primary and secondary schools, with totally at least 10000 participants were randomly selected (Primary: Secondary=1:1). All of the selected schools were randomly allocated to either intervention or control group (Intervention: Control=1:1).The multi-components school-based and family-involved scheme was conducted within the intervention group for 9 month, while students in the control group followed their usual health practice. The intervention consisted of four components: a) Create supportive school and family environment, b) Health lifestyles education and related compulsory physical activities, c) Instruct and promote school physical education, d) Self-monitor obesity related behaviors. Four types of outcomes including anthropometric, behavioral, blood chemical and physical fitness were measured to assess the effectiveness of the intervention program.


Options:
A: Arm Label: MOVI-da 10! active breaks; Type: EXPERIMENTAL; Interventions: Behavioral: MOVI-da10! active breaks | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MOVI-da10! integrated physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: MOVI-da10! integrated physical activity | Intervention Type: BEHAVIORAL; Name: MOVI-da10! active breaks; Assigned to Arm(s): MOVI-da 10! active breaks | Intervention Type: BEHAVIORAL; Name: MOVI-da10! integrated physical activity; Assigned to Arm(s): MOVI-da10! integrated physical activity
B: Arm Label: A Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Increased physical education in primary school (daily) | Arm Label: B Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increased physical education in primary school (daily); Assigned to Arm(s): A Intervention group
C: Arm Label: The Health Lifestyles Interventions; Type: EXPERIMENTAL; Interventions: Behavioral: The Health Lifestyles Interventions | Arm Label: Receive no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Health Lifestyles Interventions; Assigned to Arm(s): The Health Lifestyles Interventions
D: Arm Label: multicomponent intervention; Type: EXPERIMENTAL; Interventions: Behavioral: a multicomponent intervention | Arm Label: usual-care control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: a multicomponent intervention; Assigned to Arm(s): multicomponent intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Application of Appropriate Technology for Obesity Prevention and Control in Seven Centers in China
Brief Summary: The study was designed as a national multi-centered cluster randomized controlled trial involving more than 70,000 children and adolescents aged 7-18 years from 7 provinces in China. In each center, about 12-16 primary and secondary schools, with totally at least 10000 participants were randomly selected (Primary: Secondary=1:1). All of the selected schools were randomly allocated to either intervention or control group (Intervention: Control=1:1).The multi-components school-based and family-involved scheme was conducted within the intervention group for 9 month, while students in the control group followed their usual health practice. The intervention consisted of four components: a) Create supportive school and family environment, b) Health lifestyles education and related compulsory physical activities, c) Instruct and promote school physical education, d) Self-monitor obesity related behaviors. Four types of outcomes including anthropometric, behavioral, blood chemical and physical fitness were measured to assess the effectiveness of the intervention program.


Options:
A: Arm Label: Group 1:; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care management | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Standard care management | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Behavioral: The strengthened care management | Intervention Type: BEHAVIORAL; Name: Standard care management; Assigned to Arm(s): Group 1:, Group 2 | Intervention Type: BEHAVIORAL; Name: The strengthened care management; Assigned to Arm(s): Group 3
B: Arm Label: "Fortaleça sua Saúde" program; Type: EXPERIMENTAL; Interventions: Behavioral: "Fortaleça sua Saúde" program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: "Fortaleça sua Saúde" program; Assigned to Arm(s): "Fortaleça sua Saúde" program
C: Arm Label: The Health Lifestyles Interventions; Type: EXPERIMENTAL; Interventions: Behavioral: The Health Lifestyles Interventions | Arm Label: Receive no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Health Lifestyles Interventions; Assigned to Arm(s): The Health Lifestyles Interventions
D: Arm Label: HEALTH[e]TEEN; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HEALTH[e]TEEN | Arm Label: HEALTH[e]TEEN + CST; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HEALTH[e]TEEN + CST | Intervention Type: BEHAVIORAL; Name: HEALTH[e]TEEN; Assigned to Arm(s): HEALTH[e]TEEN | Intervention Type: BEHAVIORAL; Name: HEALTH[e]TEEN + CST; Assigned to Arm(s): HEALTH[e]TEEN + CST

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Resistance Training on Muscle Strength and Nutritional Status in Patients With Liver Cirrhosis
Brief Summary: The purpose is to investigate the effect of strength training on muscle strength, muscle mass and nutritional status in patients with liver cirrhosis to clarify possible metabolic and inflammatory changes during this intervention. In addition the investigator examine if the intervention is associated with fewer hospital readmission and an improved quality of life.


Options:
A: Arm Label: Exercise, relaxation; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise + relaxation | Arm Label: Relaxation; Type: OTHER; Interventions: Other: Relaxation | Intervention Type: OTHER; Name: Exercise + relaxation; Assigned to Arm(s): Exercise, relaxation | Intervention Type: OTHER; Name: Relaxation; Assigned to Arm(s): Relaxation
B: Arm Label: Exercise + Leucine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Leucine supplements | Arm Label: Leucine without exercise; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Leucine supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Leucine supplements; Assigned to Arm(s): Exercise + Leucine, Leucine without exercise
C: Arm Label: Diet+Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Diet + exercise | Intervention Type: BEHAVIORAL; Name: Diet + exercise; Assigned to Arm(s): Diet+Exercise
D: Arm Label: Nutrition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nutrition | Arm Label: Nutrition and strength training; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition and strength training | Intervention Type: BEHAVIORAL; Name: Nutrition and strength training; Assigned to Arm(s): Nutrition and strength training | Intervention Type: BEHAVIORAL; Name: Nutrition; Assigned to Arm(s): Nutrition

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Perioperative Endothelial Dysfunction in Patients Undergoing Non-cardiac Surgery
Brief Summary: More than one in 100 otherwise healthy patients undergoing non-cardiac surgery will die within 30 days post-operatively, and of these patients 45% will die from vascular causes such as myocardial infarction. The pathogenesis of perioperative myocardial infarction is complex and to date not fully elucidated. The physiological stress response associated with the surgical procedure is believed to be central in the development of perioperative cardiovascular complications. Surgery initiates systemic inflammation, hypercoagulability and increases the production of catecholamines and cortisol. These drastic systemic changes lead to a state of myocardial oxygen supply-demand mismatch, which added to acute endothelial dysfunction and ruptures of vulnerable plaques, may result in myocardial injury.

The endothelium is a regulator of vascular homeostasis, vascular tone and structure and exerts anticoagulant, antiplatelet and fibrinolytic properties. Endothelial dysfunction is characterized by a decreased vascular bioavailability of nitric oxide probably due to an increased degradation of nitric oxide via its interaction with locally produced reactive oxygen species. No clinical studies have investigated whether peri- and postoperative endothelial dysfunction is associated with an increased risk of perioperative myocardial injury. Endothelial dysfunction may be a key element in the development of perioperative myocardial injury.

The aim of this observational clinical study is to closely examine the endothelial function and its dynamics in the early postoperative period.


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo) | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Matching placebo for Rivaroxaban arm (Warfarin placebo); Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Matching placebo for Warfarin arm (Rivaroxaban placebo); Assigned to Arm(s): Warfarin
B: N/A
C: Intervention Type: PROCEDURE; Name: Elective colon cancer surgery; Assigned to Arm(s): N/A
D: Arm Label: DSE; Type: N/A; Interventions: N/A | Arm Label: CTCA; Type: N/A; Interventions: N/A

Answer: C